STAT+: At Stanford conference, typically guarded biotech leaders share their concerns about Trump policies
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
PALO ALTO, Calif. \u2014 At an annual meeting usually focused on the industry\u2019s future, life science leaders couldn\u2019t help but grapple \u2014 100 days<\/a> into President Trump\u2019s second term \u2014\u00a0with a present clouded by uncertainty.<\/p>\n At Stanford\u2019s Drug Discovery Symposium, biotech bigwigs spoke openly this week about how the scientific ecosystem that trains the industry\u2019s workforce and produces many of the discoveries companies later turn into new drugs and diagnostics is now in jeopardy. And investors said the administration\u2019s shifting funding priorities and layoffs at the Food and Drug Administration<\/a> are already impacting what areas they\u2019re willing to fund and where portfolio companies run clinical trials.<\/p>\n \u201cSome of the fundamental, foundational elements on which this industry was so successful look more uncertain now than in my 40 years in the industry,\u201d said Robert Bradway, chairman and CEO of Amgen, pointing both to the current administration and market trends and shifts in drug pricing policy that preceded Trump.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n